Fly News Breaks for February 27, 2015
BMY
Feb 27, 2015 | 08:29 EDT
Argus increased its price target on Bristol-Myers, as the firm believes that the company's Opdivo drug for melanoma looks very promising and could become a blockbuster drug with sales of over $1B. The firm keeps a Buy rating on the stock.
News For BMY From the Last 2 Days